Reviewgold2010

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers

Jakub Adamski · Brian Godman · Gabriella Ofierska-Sujkowska · Bogusława Osińska · Harald Herholz · Kamila Wendykowska +10 more

255 citations0/0 files storedBMC Health Services Research

No readable copy stored yet — this record is metadata only.

Pharmaceutical Economics and Policy Health Systems, Economic Evaluations, Quality of Life Pharmaceutical industry and healthcare

Abstract

BACKGROUND: There has been an increase in 'risk sharing' schemes for pharmaceuticals between healthcare institutions and pharmaceutical companies in Europe in recent years as an additional approach to provide continued comprehensive and equitable healthcare. There is though confusion surrounding the terminology as well as concerns with existing schemes. METHODS: A literature review was undertaken to identify existing schemes supplemented with additional internal documents or web-based references known to the authors. This was combined with the extensive knowledge of health authority personnel from 14 different countries and locations involved with these schemes. RESULTS AND DISCUSSION: A large number of 'risk sharing' schemes with pharmaceuticals are in existence incorporating both financial-based models and performance-based/outcomes-based models. In view of this, a new logical definition is proposed. This is "risk sharing' schemes should be considered as agreements concluded by payers and pharmaceutical companies to diminish the impact on payers' budgets for new and existing schemes brought about by uncertainty and/or the need to work within finite budgets". There are a number of concerns with existing schemes. These include potentially high administration costs, lack of transparency, conflicts of interest, and whether health authorities will end up funding an appreciable proportion of a new drug's development costs. In addition, there is a paucity of published evaluations of existing schemes with pharmaceuticals. CONCLUSION: We believe there are only a limited number of situations where 'risk sharing' schemes should be considered as well as factors that should be considered by payers in advance of implementation. This includes their objective, appropriateness, the availability of competent staff to fully evaluate proposed schemes as well as access to IT support. This also includes whether systematic evaluations have been built into proposed schemes.

Citations in this library

Stored only when both papers are in the corpus — 255 citations exist upstream.

References

2010Health systems in transition.2009Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions

Cited by

2017How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries 2015Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study 2013Managed entry agreements for pharmaceuticals: the European experience 2012Cost-Containment Policies in Public Pharmaceutical Spending in the EU 2018Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets 2014Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden 2013Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries 2017The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications

Imported from OpenAlex (CC0) — nothing here is generated.